Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2002, p. 2381-2386, Vol. 46, No. 8
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.8.2381-2386.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro
James R. Beadle,1 Caroll Hartline,2 Kathy A. Aldern,1 Natalie Rodriguez,1 Emma Harden,2 Earl R. Kern,2 and Karl Y. Hostetler1*
Department of Medicine, Veterans Affairs Medical Center, and the University of California, San Diego, La Jolla, California 92093-0676,1
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35294-21702
Received 16 November 2001/
Returned for modification 5 February 2002/
Accepted 18 April 2002
The incidence of cytomegalovirus (CMV) retinitis is declining in AIDS patients but remains a significant clinical problem in patients with organ transplants and bone marrow transplants. Prophylaxis with ganciclovir (GCV) or valganciclovir reduces the incidence of CMV disease but may lead to the emergence of drug-resistant virus with mutations in the UL97 or UL54 gene. It would be useful to have other types of oral therapy for CMV disease. We synthesized hexadecyloxypropyl and octadecyloxyethyl derivatives of cyclic cidofovir (cCDV) and cidofovir (CDV) and found that these novel analogs had 2.5- to 4-log increases in antiviral activity against CMV compared to the activities of unmodified CDV and cCDV. Multiple-log increases in activity were noted against laboratory CMV strains and various CMV clinical isolates including GCV-resistant strains with mutations in the UL97 and UL54 genes. Preliminary cell studies suggest that the increase in antiviral activity may be partially explained by a much greater cell penetration of the novel analogs. 1-O-Hexadecyloxypropyl-CDV, 1-O-octadecyloxyethyl-CDV, and their corresponding cCDV analogs are worthy of further preclinical evaluation for treatment and prevention of CMV and herpes simplex virus infections in humans.
* Corresponding author. Mailing address: Department of Medicine (0676), University of California, 305 Clinical Sciences Building, 9500 Gilman Dr., San Diego, La Jolla, CA 92093-0676. Phone: (858) 552-8585, ext. 2616. Fax: (858) 534-6133. E-mail:
khostetl{at}ucsd.edu.
Antimicrobial Agents and Chemotherapy, August 2002, p. 2381-2386, Vol. 46, No. 8
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.8.2381-2386.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Prichard, M. N., Hartline, C. B., Harden, E. A., Daily, S. L., Beadle, J. R., Valiaeva, N., Kern, E. R., Hostetler, K. Y.
(2008). Inhibition of Herpesvirus Replication by Hexadecyloxypropyl Esters of Purine- and Pyrimidine-Based Phosphonomethoxyethyl Nucleoside Phosphonates. Antimicrob. Agents Chemother.
52: 4326-4330
[Abstract]
[Full Text]
-
Quenelle, D. C., Collins, D. J., Herrod, B. P., Keith, K. A., Trahan, J., Beadle, J. R., Hostetler, K. Y., Kern, E. R.
(2007). Effect of Oral Treatment with Hexadecyloxypropyl-[(S)-9-(3-Hydroxy-2- Phosphonylmethoxypropyl)Adenine] [(S)-HPMPA] or Octadecyloxyethyl-(S)-HPMPA on Cowpox or Vaccinia Virus Infections in Mice. Antimicrob. Agents Chemother.
51: 3940-3947
[Abstract]
[Full Text]
-
Painter, G. R., Almond, M. R., Trost, L. C., Lampert, B. M., Neyts, J., De Clercq, E., Korba, B. E., Aldern, K. A., Beadle, J. R., Hostetler, K. Y.
(2007). Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections. Antimicrob. Agents Chemother.
51: 3505-3509
[Abstract]
[Full Text]
-
Lebeau, I., Andrei, G., Krecmerova, M., De Clercq, E., Holy, A., Snoeck, R.
(2007). Inhibitory Activities of Three Classes of Acyclic Nucleoside Phosphonates against Murine Polyomavirus and Primate Simian Virus 40 Strains. Antimicrob. Agents Chemother.
51: 2268-2273
[Abstract]
[Full Text]
-
Choo, H., Beadle, J. R., Kern, E. R., Prichard, M. N., Keith, K. A., Hartline, C. B., Trahan, J., Aldern, K. A., Korba, B. E., Hostetler, K. Y.
(2007). Antiviral Activities of Novel 5-Phosphono-Pent-2-en-1-yl Nucleosides and Their Alkoxyalkyl Phosphonoesters. Antimicrob. Agents Chemother.
51: 611-615
[Abstract]
[Full Text]
-
Kornbluth, R. S., Smee, D. F., Sidwell, R. W., Snarsky, V., Evans, D. H., Hostetler, K. Y.
(2006). Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR Are Associated with the Drug Resistance Phenotype. Antimicrob. Agents Chemother.
50: 4038-4043
[Abstract]
[Full Text]
-
Hostetler, K. Y., Aldern, K. A., Wan, W. B., Ciesla, S. L., Beadle, J. R.
(2006). Alkoxyalkyl esters of (s)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.. Antimicrob. Agents Chemother.
50: 2857-2859
[Abstract]
[Full Text]
-
Lebeau, I., Andrei, G., Dal Pozzo, F., Beadle, J. R., Hostetler, K. Y., De Clercq, E., van den Oord, J., Snoeck, R.
(2006). Activities of Alkoxyalkyl Esters of Cidofovir (CDV), Cyclic CDV, and (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine against Orthopoxviruses in Cell Monolayers and in Organotypic Cultures.. Antimicrob. Agents Chemother.
50: 2525-2529
[Abstract]
[Full Text]
-
Randhawa, P., Farasati, N. A., Shapiro, R., Hostetler, K. Y.
(2006). Ether Lipid Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro.. Antimicrob. Agents Chemother.
50: 1564-1566
[Abstract]
[Full Text]
-
Hostetler, K. Y., Rought, S., Aldern, K. A., Trahan, J., Beadle, J. R., Corbeil, J.
(2006). Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Molecular Cancer Therapeutics
5: 156-159
[Abstract]
[Full Text]
-
Williams-Aziz, S. L., Hartline, C. B., Harden, E. A., Daily, S. L., Prichard, M. N., Kushner, N. L., Beadle, J. R., Wan, W. B., Hostetler, K. Y., Kern, E. R.
(2005). Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro. Antimicrob. Agents Chemother.
49: 3724-3733
[Abstract]
[Full Text]
-
Wan, W. B., Beadle, J. R., Hartline, C., Kern, E. R., Ciesla, S. L., Valiaeva, N., Hostetler, K. Y.
(2005). Comparison of the Antiviral Activities of Alkoxyalkyl and Alkyl Esters of Cidofovir against Human and Murine Cytomegalovirus Replication In Vitro. Antimicrob. Agents Chemother.
49: 656-662
[Abstract]
[Full Text]
-
Cheng, L., Hostetler, K. Y., Lee, J., Koh, H. J., Beadle, J. R., Bessho, K., Toyoguchi, M., Aldern, K., Bovet, J.-M., Freeman, W. R.
(2004). Characterization of a Novel Intraocular Drug-Delivery System Using Crystalline Lipid Antiviral Prodrugs of Ganciclovir and Cyclic Cidofovir. IOVS
45: 4138-4144
[Abstract]
[Full Text]
-
Kern, E. R., Collins, D. J., Wan, W. B., Beadle, J. R., Hostetler, K. Y., Quenelle, D. C.
(2004). Oral Treatment of Murine Cytomegalovirus Infections with Ether Lipid Esters of Cidofovir. Antimicrob. Agents Chemother.
48: 3516-3522
[Abstract]
[Full Text]
-
Kern, E. R., Hartline, C. B., Rybak, R. J., Drach, J. C., Townsend, L. B., Biron, K. K., Bidanset, D. J.
(2004). Activities of Benzimidazole D- and L-Ribonucleosides in Animal Models of Cytomegalovirus Infections. Antimicrob. Agents Chemother.
48: 1749-1755
[Abstract]
[Full Text]
-
Keith, K. A., Wan, W. B., Ciesla, S. L., Beadle, J. R., Hostetler, K. Y., Kern, E. R.
(2004). Inhibitory Activity of Alkoxyalkyl and Alkyl Esters of Cidofovir and Cyclic Cidofovir against Orthopoxvirus Replication In Vitro. Antimicrob. Agents Chemother.
48: 1869-1871
[Abstract]
[Full Text]
-
Quenelle, D. C., Collins, D. J., Wan, W. B., Beadle, J. R., Hostetler, K. Y., Kern, E. R.
(2004). Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir. Antimicrob. Agents Chemother.
48: 404-412
[Abstract]
[Full Text]
-
De Clercq, E.
(2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev.
16: 569-596
[Abstract]
[Full Text]
-
Williams, S. L., Hartline, C. B., Kushner, N. L., Harden, E. A., Bidanset, D. J., Drach, J. C., Townsend, L. B., Underwood, M. R., Biron, K. K., Kern, E. R.
(2003). In Vitro Activities of Benzimidazole D- and L-Ribonucleosides against Herpesviruses. Antimicrob. Agents Chemother.
47: 2186-2192
[Abstract]
[Full Text]
-
Keith, K. A., Hitchcock, M. J. M., Lee, W. A., Holy, A., Kern, E. R.
(2003). Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication. Antimicrob. Agents Chemother.
47: 2193-2198
[Abstract]
[Full Text]
-
Stebbing, J., Portsmouth, S., Gazzard, B.
(2003). How does HAART lead to the resolution of Kaposi's sarcoma?. J Antimicrob Chemother
51: 1095-1098
[Full Text]
-
Aldern, K. A., Ciesla, S. L., Winegarden, K. L., Hostetler, K. Y.
(2003). Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism. Mol. Pharmacol.
63: 678-681
[Abstract]
[Full Text]